Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

The drug in question is sozinibercept, an inhibitor of vascular endothelial growth factors (VEGFs) C and D. Atea had been evaluating a 2-mg dose of sozinibercept every four or eight weeks in ...

Opthia could owe its investors more than $1bn following the results of its Phase III Combination OPT-302 with Aflibercept Study (COAST) trial (NCT04757636), which evaluated its sozinibercept ...

Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study. Opthea on Monday ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Register for free now. The trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg Regeneron Pharmaceuticals ...

The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks ...

Perspective from Rishi P. Singh, MD Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release. After the March 24 release of ...